Abstract: Provided herein are water soluble salts of Formula I, wherein R1, A, and M are defined herein. Also provided herein are methods of preparing the salts of Formula I and methods of using the same.

Abstract: Novel N2-phenylpyrimidine-2,4-diamine compounds, method for preparing the same, and pharmaceutical composition or health functional food are disclosed. The novel N2-phenylpyrimidine-2,4-diamine compounds show potent inhibitory efficacies on EGFR mutations and thus, can be effectively used for the treatment of cancer with EGFR mutations.

Abstract: The present invention relates to a pharmaceutical formulation having excellent bioavailability and stability, comprising sodium palmitoyl-L-prolyl-L-prolyl-glycyl-L-tyrosinate (Compound I) as an active ingredient. The pharmaceutical formulation according to the present invention can be usefully used as a dosage form for treating inflammatory bowel disease and the like since Compound I, an active ingredient, is not decomposed in the stomach and released in the intestine.

Abstract: Provided herein are water soluble salts of Formula I, wherein R1, A, and M are defined herein. Also provided herein are methods of preparing the salts of Formula I and methods of using the same.

Abstract: Novel compounds that are potent inhibitors of hepatitis C virus protease are provided. Pharmaceutical compositions containing one or more of these inhibitors, methods of preparing the inhibitors and methods of using the inhibitors to treat hepatitis C and related disorders also are provided.

Abstract: This invention relates to a series of substituted cyclohexane containing analogues which are agonists of GPR119 intended to treat metabolic diseases mediated by GPR119 including Type I & II diabetes mellitus. Diabetes mellitus is an ever-increasing threat to human health causing various complications (blindness, kidney failure, neuropathy, heart attack, stroke, etc.). Recently it was found that activation of GPR119 which is highly expressed in pancreatic beta cells causes glucose dependent insulin secretion and GLP-1 release. Many pharmaceuticals are currently developing GPR119 agonists and herein we disclose alternative GPR119 agonists. Our invention describes GPR119 agonists having structural Formula (I), pharmaceutically acceptable salt or solvate of Formula (I), isomer or prodrug of Formula (I), and combination therapy of Formula (I) with other anti-diabetic drugs like DPP-IV inhibitors and/or insulin sensitizers.

Abstract: Novel compounds that are potent inhibitors of hepatitis C virus protease are provided. Pharmaceutical compositions containing one or more of these inhibitors, methods of preparing the inhibitors and methods of using the inhibitors to treat hepatitis C and related disorders also are provided.

Abstract: Disclosed are compounds represented by the formula: or a pharmaceutically acceptable salt or isomer thereof, wherein R1-R6 are as defined in the specification. These compounds are targeted for use as inhibitors of SH2 domain binding with a phosphoprotein, and are contemplated for use in a number of diseases including cancer. Also disclosed are pharmaceutical compositions comprising a compound of the invention and a pharmaceutically acceptable carrier.

Abstract: Disclosed are compounds represented by the formula: or a pharmaceutically acceptable salt or isomer thereof, wherein R1-R6 are as defined in the specification. These compounds are targeted for use as inhibitors of SH2 domain binding with a phosphoprotein, and are contemplated for use in a number of diseases including cancer. Also disclosed are pharmaceutical compositions comprising a compound of the invention and a pharmaceutically acceptable carrier.

Abstract: A method and apparatus for controlling buffering of an audio stream so that audio can be played continuously without stoppage using a minimum amount of buffering are provided. The method for controlling buffering of data includes (a) determining a buffering period of compressed audio data on the basis of a time stamp which corresponds to a packet division unit, by considering the state of a network, (b) calculating a time period where the compressed audio data is to be stored in a buffer, on the basis of the buffering period that is determined in step (a), (c) buffering the inputted compressed audio data in a decoding buffer for the time period that is calculated in step (b), and (d) decoding the compressed audio data that is stored in the decoding buffer when the time period passes in step (c) and storing the decoded audio data in a composition buffer for synchronization with video data.

Abstract: Disclosed are compounds represented by the formula: or a pharmaceutically acceptable salt or isomer thereof, wherein R1-R6 are as defined in the specification. These compounds are targeted for use as inhibitors of SH2 domain binding with a phosphoprotein, and are contemplated for use in a number of diseases including cancer. Also disclosed are pharmaceutical compositions comprising a compound of the invention and a pharmaceutically acceptable carrier.

Abstract: A method and apparatus for controlling buffering of an audio stream so that audio can be played continuously without stoppage using a minimum amount of buffering are provided. The method for controlling buffering of data includes (a) determining a buffering period of compressed audio data on the basis of a time stamp which corresponds to a packet division unit, by considering the state of a network, (b) calculating a time period where the compressed audio data is to be stored in a buffer, on the basis of the buffering period that is determined in step (a), (c) buffering the inputted compressed audio data in a decoding buffer for the time period that is calculated in step (b), and (d) decoding the compressed audio data that is stored in the decoding buffer when the time period passes in step (c) and storing the decoded audio data in a composition buffer for synchronization with video data.